Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. (TNXP) disclosed preliminary estimates for the three months ended September 30, 2026, including TONMYA net revenue of $14.0 million to $15.0 million. Estimated cash and cash equivalents were approximately $162.8 million as of September 30, 2026.
The company has not completed its financial closing procedures. The estimates are subject to completion and revision, and actual results could be materially different.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a new agreement with a pharmacy benefit manager, effective immediately, that provides TONMYA coverage to approximately 21 million Medicare Part D beneficiaries. This second major managed Medicare agreement raises TONMYA’s Medicare coverage to 32 million lives, or 58% of roughly 55 million Medicare lives in the U.S.
Total commercial and government payer coverage for TONMYA now reaches about 166 million covered lives, representing 53% of approximately 314 million total U.S. lives. Tonix highlighted TONMYA as the first new prescription medicine approved for fibromyalgia in more than 15 years, with U.S. patents expected to provide market exclusivity until 2034, and noted that its sales force has expanded to 150 representatives to support the product launch.
Tonix Pharmaceuticals Holding Corp. (TNXP) announced the promotion of Thomas Englese, MBA, to Chief Commercial Officer, effective September 8, 2026. He has led Tonix’s commercial organization and the U.S. launch of TONMYA, and will continue overseeing sales, marketing, market access, and commercial operations for TONMYA and the acute migraine products Zembrace SymTouch and Tosymra.
The disclosure also reiterates the approved indication, contraindications, major warnings, and adverse reactions for TONMYA, including risks related to pregnancy, serotonin syndrome with concomitant serotonergic drugs, CNS depression, tricyclic antidepressant-like effects, and specific considerations for hepatic impairment, lactation, pediatric, and geriatric use.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported the initial beneficial ownership of its Chief Commercial Officer, Thomas Englese, on a Form 3. He holds 694 shares of common stock directly and several stock options covering 500, 6,500, 12,480 and 40,000 underlying common shares, with exercise prices between $8.05 and $20.18 and expirations from September 9, 2034 to February 24, 2036. Footnotes state these options were granted under Tonix’s Amended and Restated 2020 Stock Incentive Plan and vest over three- or four-year schedules starting on each grant’s first anniversary.
Tonix Pharmaceuticals Holding Corp. (TNXP) director and Chief Executive Officer Seth Lederman reported buying common stock on August 27, 2026. An IRA account associated with him purchased 2,000 shares of common stock at $13.79 per share in an open-market or private transaction, held as indirect ownership. After this purchase, the IRA account held 11,005 shares. Separate from this, he also reported 20,001 shares held directly and 1 share held indirectly through Lederman & Co., for which he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. (TNXP) director Richard H. Bagger reported purchasing 1,000 shares of the company’s common stock on August 20, 2026. The shares were bought at a price of $12.60 per share, and he now holds 1,000 shares of Tonix common stock directly.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported that on August 18, 2026, its Board of Directors appointed Dr. Seth Lederman, the company’s President, Chief Executive Officer and Chairman of the Board, as Interim Chief Medical Officer. Dr. Lederman, age 69, has held his existing leadership roles since October 2011 and will continue to serve in all of these positions concurrently.
The company states there are no arrangements or understandings with any other person related to his appointment, and no family relationships between Dr. Lederman and any director or executive officer. Tonix publicly announced his appointment as Interim Chief Medical Officer on the same date.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Tonix Pharmaceuticals Holding Corp. common stock. They report control over 814,801 shares of Common Stock, including 615,025 shares issuable upon exercise of warrants, representing 4.9% of the class.
The ownership percentage is based on 15,940,801 shares of Common Stock outstanding as of May 8, 2026 and assumes exercise of the warrants held by funds managed by Sirenia. Voting and dispositive powers over these shares are reported on a shared basis, with no sole voting or dispositive power.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 882,595 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing 5.54% of the class. They report shared voting power over 866,867 shares and shared dispositive power over 882,595 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule 13G is filed on behalf of both entities.